Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC3 | Q13507 | 2/20 | 0.55 |
| ▸ | BCHE | P06276 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4434921 | 0.78 | TRPC3 (0.56) | TRPC3BCHEACHEHTR3AMAPT | |
| SCHEMBL4433260 | 0.77 | TRPC3 (0.55) | TRPC3BCHEACHEHTR3AMAPT | |
| SCHEMBL22481379 | 0.73 | TRPC3 (0.75) | TRPC3BCHEACHEHTR3AMAPT | |
| SCHEMBL13450331 | 0.72 | TRPC3 (1.00) | TRPC3BCHEACHEHTR3AMAPT | |
| SCHEMBL7848240 | 0.72 | TRPC3 (0.73) | TRPC3BCHEACHEHTR3AMAPT | |
| SCHEMBL2676103 | 0.70 | BCHE (0.96) | TRPC3BCHEACHEHTR3AMAPT | |
| SCHEMBL2674037 | 0.70 | BCHE (0.90) | TRPC3BCHEACHEHTR3AMAPT | |
| SCHEMBL9369695 | 0.69 | TRPC3 (0.68) | TRPC3BCHEACHEHTR3AMAPT | |
| SCHEMBL4713162 | 0.69 | TRPC3 (0.68) | TRPC3BCHEACHEHTR3AMAPT | |
| SCHEMBL717865 | 0.68 | BCHE (1.00) | TRPC3BCHEACHEHTR3AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239880-A1 | COMBINATIONS OF MONOAMINE REUPTAKE INHIBITORS AND POTASSIUM CHANNEL ACTIVATORS | NEUROSEARCH A/S (DK) | 2009-09-24 | — | — | US | claimed |
| US-20090239880-A1 | COMBINATIONS OF MONOAMINE REUPTAKE INHIBITORS AND POTASSIUM CHANNEL ACTIVATORS | NEUROSEARCH A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| EP-2043641-A2 | COMBINATIONS OF MONOAMINE REUPTAKE INHIBITORS AND POTASSIUM CHANNEL ACTIVATORS | NeuroSearch A/S (DK) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008003667-A2 | COMBINATIONS OF MONOAMINE REUPTAKE INHIBITORS AND POTASSIUM CHANNEL ACTIVATORS | NEUROSEARCH A/S (DK) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239880-A1 | COMBINATIONS OF MONOAMINE REUPTAKE INHIBITORS AND POTASSIUM CHANNEL ACTIVATORS | SLC6A2, SLC18A2, SLC6A4 | TRPC3 232/4885BCHE 1229/4885ACHE 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.